<DOC>
	<DOCNO>NCT00752557</DOCNO>
	<brief_summary>The main purpose study ass whether locally-administered rhBMP-2/CPM injection rapidly increase bone mass subject high risk osteoporotic fracture hip . All subject receive standard treatment low bone mass , consist bisphosphonates , calcium , vitamin D ( take mouth ) . Subjects randomly select receive treatment rhBMP-2 receive injection directly hip . The injection give surgery room use light anesthesia .</brief_summary>
	<brief_title>Study Evaluating Changes In Bone Mineral Density ( BMD ) , And Safety Of Rhbmp-2/CPM In Subjects With Decreased BMD</brief_title>
	<detailed_description />
	<mesh_term>Osteoporosis</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin D</mesh_term>
	<mesh_term>Ergocalciferols</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Communitydwelling , ambulatory ( without assistive device ) , postmenopausal female , age great 65 year . BMD Tscore ( total hip femoral neck ) 2.5 less least 1 hip . Subjects BMD Tscores 2.0 le may enrol least one follow risk factor also present : Age great 75 year Family ( maternal ) history fragility fracture Previous fragility fracture ( self ) age 45 Subjects may either treatment na√Øve previouslyestablished regimen ( great 1year , less 5 year duration ) bisphosphonate therapy . Subjects must willing comply 1of 3 protocoldesignated oral bisphosphonates ( risedronate , alendronate , ibandronate sodium ) risedronate consider firstline therapy . Metabolic bone disorder disease affect bone mineral metabolism ( eg , Paget 's disease , vitamin D deficiency [ le 20 ng/mL ] , hyperparathyroidism , renal osteodystrophy , osteomalacia , hypocalcemia , hypercalcemia ) . Coagulopathy and/or history venous thromboembolic event ( deep vein thrombosis , pulmonary embolus , retinal vein thrombosis ) within past 12 month . Inflammatory arthritis include rheumatoid , psoriatic , crystalinduced ( gouty ) arthritis , associate systemic lupus erythematosus ( SLE ) , spondyloarthropathy , Reiters syndrome , Crohns disease .</criteria>
	<gender>Female</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Bone mineral density</keyword>
	<keyword>bone morphogenetic protein</keyword>
	<keyword>osteoporosis</keyword>
</DOC>